Discover 859 paid clinical trials in Tuscaloosa, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 859
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Birmingham AL, Atlanta GA, Pensacola FL, New Orleans LA,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06580314
Phase3, Recruiting
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
for
Migraine
Location: Birmingham AL, Ridgeland MS, Mobile AL, Marietta GA,
Sponsor: Kallyope Inc.
Sex: All
Age: 18 - 70+
Code: NCT07645924
Phase3, Recruiting
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
for
Type 2 Diabetes
Location: Birmingham AL, Cordele GA, Winter Park FL, Houston TX,
Sponsor: Biomea Fusion Inc.
Sex: All
Age: 18 - 70
Code: NCT07502508
Phase2, Recruiting
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
for
Acute Migraine
Location: Birmingham AL, Ridgeland MS, Mobile AL, Marietta GA,
Sponsor: Kallyope Inc.
Sex: All
Age: 18+
Code: NCT07674654
Phase3, Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
for
Chronic Inflammatory Demyelinating Polyneuropathy
Location: Birmingham AL, Nashville TN, Edwardsville IL,
Sponsor: Dianthus Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT06858579
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
for
Generalized Myasthenia Gravis
Location: Birmingham AL, Chattanooga TN, Knoxville TN, Augusta GA,
Sponsor: Alexion Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT04202341
Recruiting
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
for
Alpha 1-Antitrypsin Deficiency
Location: Birmingham AL, Charleston SC, Boston MA
Sponsor: Beam Therapeutics Inc.
Sex: All
Age: 18 - 70
Code: NCT06389877
Phase1, Phase2, Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
for
Peripheral Arterial Disease
Location: Birmingham AL, Jackson TN, Jefferson City TN,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07223593
Phase3, Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
for
Acute Hepatic Porphyria
Location: Birmingham AL, Galveston TX, Oklahoma City OK,
Sponsor: Alnylam Pharmaceuticals
Sex: All
Age: 12+
Code: NCT04883905
Recruiting
Bucillamine Phase 2 Trial in Patients With Cystinuria
for
Cystinuria
Location: Birmingham AL, Madison WI, New York NY, Warwick RI,
Sponsor: Revive Therapeutics, Ltd.
Sex: All
Age: 18 - 70+
Code: NCT02942420
Phase2, Recruiting
Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention
for
HIV Seropositivity
Location: Birmingham AL, Huntsville AL, Chicago IL
Sponsor: University of Chicago
Sex: All
Age: 18 - 49
Code: NCT05723653
Recruiting
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
for
HIV Infections
Location: Birmingham AL, Atlanta GA, Pensacola FL, New Orleans LA,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT07473778
Recruiting
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
for
HIV
Location: Birmingham AL, Atlanta GA, Boston MA, Seattle WA
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All
Age: 18 - 60
Code: NCT07569029
Phase1, Recruiting
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1